Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

stryker corp. - SYK

SYK

Close Chg Chg %
388.65 -3.01 -0.78%

Pre-Market

385.64

-3.01 (0.78%)

Volume: 1.10M

Last Updated:

Nov 20, 2024, 3:59 PM EDT

Trade Now

Company Overview: stryker corp. - SYK

SYK Key Data

Open

$389.70

 Day Range

382.25 - 389.98

52 Week Range

286.30 - 398.15

 Market Cap

$148.17B

Shares Outstanding

381.22M

 Public Float

357.30M

Beta

0.92

 Rev. Per Employee

N/A

P/E Ratio

41.67

 EPS

$9.43

Yield

82.33%

 Dividend

$0.80

EX-DIVIDEND DATE

Sep 30, 2024

 SHORT INTEREST

N/A

AVERAGE VOLUME

1.42M

  

SYK Performance

1 Week
 
 -1.13%
 
1 Month
 
 4.36%
 
3 Months
 
 9.17%
 
1 Year
 
 31.34%
 
5 Years
 
 91.32%
 

SYK Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 33
Full Ratings ➔

About stryker corp. - SYK

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

SYK At a Glance

Stryker Corp.
1941 Stryker Way
Portage, Michigan 49002
Phone 1-269-385-2600 Revenue 20.50B
Industry Medical Specialties Net Income 3.17B
Sector Health Technology 2023 Sales Growth 11.106%
Fiscal Year-end 12 / 2024 Employees 52,000
View SEC Filings

SYK Valuation

P/E Current 41.673
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 36.304
Price to Sales Ratio 5.606
Price to Book Ratio 6.122
Price to Cash Flow Ratio 30.963
Enterprise Value to EBITDA 23.61
Enterprise Value to Sales 6.115
Total Debt to Enterprise Value 0.108

SYK Efficiency

Revenue/Employee 394,192.308
Income Per Employee 60,865.385
Receivables Turnover 5.444
Total Asset Turnover 0.534

SYK Liquidity

Current Ratio 1.58
Quick Ratio 0.969
Cash Ratio 0.385

SYK Profitability

Gross Margin 60.952
Operating Margin 20.885
Pretax Margin 17.919
Net Margin 15.441
Return on Assets 8.243
Return on Equity 17.978
Return on Total Capital 9.864
Return on Invested Capital 10.787

SYK Capital Structure

Total Debt to Total Equity 72.576
Total Debt to Total Capital 42.054
Total Debt to Total Assets 33.809
Long-Term Debt to Equity 60.544
Long-Term Debt to Total Capital 35.083
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Stryker Corp. - SYK

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
14.35B 17.11B 18.45B 20.50B
Sales Growth
-3.58% +19.21% +7.84% +11.11%
Cost of Goods Sold (COGS) incl D&A
5.60B 6.40B 7.41B 8.00B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
812.00M 990.00M 998.00M 1.03B
Depreciation
340.00M 371.00M 371.00M 393.00M
Amortization of Intangibles
472.00M 619.00M 627.00M 635.00M
COGS Growth
+1.74% +14.31% +15.78% +8.03%
Gross Income
8.75B 10.71B 11.04B 12.49B
Gross Income Growth
-6.70% +22.35% +3.09% +13.17%
Gross Profit Margin
+60.99% +62.60% +59.84% +60.95%
2020 2021 2022 2023 5-year trend
SG&A Expense
5.80B 7.05B 7.31B 8.21B
Research & Development
984.00M 1.24B 1.23B 1.29B
Other SG&A
4.82B 5.81B 6.08B 6.92B
SGA Growth
-3.17% +21.43% +3.66% +12.41%
Other Operating Expense
- - - -
-
Unusual Expense
706.00M 1.06B 853.00M 334.00M
EBIT after Unusual Expense
2.24B 2.60B 2.88B 3.95B
Non Operating Income/Expense
26.00M 21.00M 139.00M 82.00M
Non-Operating Interest Income
102.00M 68.00M 94.00M 75.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
315.00M 337.00M 337.00M 356.00M
Interest Expense Growth
- +9.76% +6.98% +5.64%
Gross Interest Expense
315.00M 337.00M 337.00M 356.00M
Interest Capitalized
- - - -
-
Pretax Income
1.95B 2.28B 2.68B 3.67B
Pretax Income Growth
-23.73% +16.73% +17.62% +36.90%
Pretax Margin
+13.62% +13.33% +14.54% +17.92%
Income Tax
355.00M 287.00M 325.00M 508.00M
Income Tax - Current - Domestic
100.00M 252.00M (12.00M) 284.00M
Income Tax - Current - Foreign
207.00M 272.00M 279.00M 430.00M
Income Tax - Deferred - Domestic
(24.00M) (105.00M) (209.00M) (232.00M)
Income Tax - Deferred - Foreign
72.00M (132.00M) 267.00M 26.00M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
1.60B 1.99B 2.36B 3.17B
Minority Interest Expense
- - - -
-
Net Income
1.60B 1.99B 2.36B 3.17B
Net Income Growth
-23.24% +24.70% +18.25% +34.22%
Net Margin Growth
+11.14% +11.66% +12.78% +15.44%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
1.60B 1.99B 2.36B 3.17B
Preferred Dividends
- - - -
-
Net Income Available to Common
1.60B 1.99B 2.36B 3.17B
EPS (Basic)
4.2583 5.2891 6.2348 8.3377
EPS (Basic) Growth
-23.54% +24.21% +17.88% +33.73%
Basic Shares Outstanding
375.50M 377.00M 378.20M 379.60M
EPS (Diluted)
4.2046 5.2158 6.1695 8.2486
EPS (Diluted) Growth
-23.32% +24.05% +18.28% +33.70%
Diluted Shares Outstanding
380.30M 382.30M 382.20M 383.70M
EBITDA
3.76B 4.65B 4.73B 5.31B
EBITDA Growth
-9.72% +23.66% +1.74% +12.19%
EBITDA Margin
+26.21% +27.19% +25.65% +25.90%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 400.24
Number of Ratings 33 Current Quarters Estimate 3.873
FY Report Date 12 / 2024 Current Year's Estimate 12.055
Last Quarter’s Earnings 2.87 Median PE on CY Estimate N/A
Year Ago Earnings 10.60 Next Fiscal Year Estimate 13.529
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 26 19 28 28
Mean Estimate 3.87 2.85 12.05 13.53
High Estimates 3.92 3.15 12.10 13.69
Low Estimate 3.84 2.69 12.02 13.16
Coefficient of Variance 0.50 4.50 0.14 0.78

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 18 18 17
OVERWEIGHT 5 4 5
HOLD 9 10 9
UNDERWEIGHT 1 1 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Stryker Corp. - SYK

Date Name Shares Transaction Value
Nov 8, 2024 Ronda E. Stryker Director 3,086,608 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $370.07 per share 1,142,261,022.56
Nov 8, 2024 Ronda E. Stryker Director 3,087,772 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $369.37 per share 1,140,530,343.64
Nov 8, 2024 Ronda E. Stryker Director 3,126,983 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $368.5 per share 1,152,293,235.50
Nov 8, 2024 Ronda E. Stryker Director 3,186,635 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $367.6 per share 1,171,407,026.00
Nov 8, 2024 Ronda E. Stryker Director 3,235,663 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $366.57 per share 1,186,096,985.91
Nov 8, 2024 Ronda E. Stryker Director 3,267,748 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $365.53 per share 1,194,459,926.44
Nov 8, 2024 Ronda E. Stryker Director 3,278,522 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $364.58 per share 1,195,283,550.76
Nov 8, 2024 Ronda E. Stryker Director 3,307,354 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $363.65 per share 1,202,719,282.10
Aug 9, 2024 Ronda E. Stryker Director 3,316,608 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $326.06 per share 1,081,413,204.48
Aug 9, 2024 Ronda E. Stryker Director 3,321,611 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $325.45 per share 1,081,018,299.95
Aug 9, 2024 Ronda E. Stryker Director 3,339,538 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $324.48 per share 1,083,613,290.24
Aug 9, 2024 Robert Fletcher VP, Chief Legal Officer 9,182 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 4, 2024 Glenn S. Boehnlein VP, Chief Financial Officer 22,852 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $336.5 per share 7,689,698.00
Jul 4, 2024 Glenn S. Boehnlein VP, Chief Financial Officer 40,012 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $122.51 per share 4,901,870.12
Jul 4, 2024 Glenn S. Boehnlein VP, Chief Financial Officer 15,815 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 14, 2024 Mary K. Brainerd Director 6,468 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 14, 2024 Rajeev Suri Director 5,868 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 14, 2024 Lisa M. Skeete Tatum Director 3,883 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 14, 2024 Giovanni Caforio Director 3,208 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 14, 2024 Andrew K. Silvernail Director 10,910 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Stryker Corp. in the News